Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis.
Adult
Amygdala
/ diagnostic imaging
Cerebral Cortex
/ diagnostic imaging
Depressive Disorder, Treatment-Resistant
/ diagnostic imaging
Electroconvulsive Therapy
Female
Hippocampus
/ diagnostic imaging
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Organ Size
Treatment Outcome
Electroconvulsive therapy
depressive disorders
imaging
inpatient treatment
Journal
The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
18
11
2018
medline:
8
2
2020
entrez:
17
11
2018
Statut:
ppublish
Résumé
Electroconvulsive therapy (ECT) is the treatment of choice for severe mental illness including treatment-resistant depression (TRD). Increases in volume of the hippocampus and amygdala following ECT have consistently been reported.AimsTo investigate neuroplastic changes after ECT in specific hippocampal subfields and amygdala nuclei using high-resolution structural magnetic resonance imaging (MRI) (trial registration: clinicaltrials.gov - NCT02379767). MRI scans were carried out in 14 patients (11 women, 46.9 years (s.d. = 8.1)) with unipolar TRD twice before and once after a series of right unilateral ECT in a pre-post study design. Volumes of subcortical structures, including subfields of the hippocampus and amygdala, and cortical thickness were extracted using FreeSurfer. The effect of ECT was tested using repeated-measures ANOVA. Correlations of imaging and clinical parameters were explored. Increases in volume of the right hippocampus by 139.4 mm3 (s.d. = 34.9), right amygdala by 82.3 mm3 (s.d. = 43.9) and right putamen by 73.9 mm3 (s.d. = 77.0) were observed. These changes were localised in the basal and lateral nuclei, and the corticoamygdaloid transition area of the amygdala, the hippocampal-amygdaloid transition area and the granule cell and molecular layer of the dentate gyrus. Cortical thickness increased in the temporal, parietal and insular cortices of the right hemisphere. Following ECT structural changes were observed in hippocampal subfields and amygdala nuclei that are specifically implicated in the pathophysiology of depression and stress-related disorders and retain a high potential for neuroplasticity in adulthood.Declaration of interestS.K. has received grants/research support, consulting fees and/or honoraria within the past 3 years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe and Servier. R.L. received travel grants and/or conference speaker honoraria from Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, and Roche Austria GmbH.
Sections du résumé
BACKGROUND
Electroconvulsive therapy (ECT) is the treatment of choice for severe mental illness including treatment-resistant depression (TRD). Increases in volume of the hippocampus and amygdala following ECT have consistently been reported.AimsTo investigate neuroplastic changes after ECT in specific hippocampal subfields and amygdala nuclei using high-resolution structural magnetic resonance imaging (MRI) (trial registration: clinicaltrials.gov - NCT02379767).
METHOD
MRI scans were carried out in 14 patients (11 women, 46.9 years (s.d. = 8.1)) with unipolar TRD twice before and once after a series of right unilateral ECT in a pre-post study design. Volumes of subcortical structures, including subfields of the hippocampus and amygdala, and cortical thickness were extracted using FreeSurfer. The effect of ECT was tested using repeated-measures ANOVA. Correlations of imaging and clinical parameters were explored.
RESULTS
Increases in volume of the right hippocampus by 139.4 mm3 (s.d. = 34.9), right amygdala by 82.3 mm3 (s.d. = 43.9) and right putamen by 73.9 mm3 (s.d. = 77.0) were observed. These changes were localised in the basal and lateral nuclei, and the corticoamygdaloid transition area of the amygdala, the hippocampal-amygdaloid transition area and the granule cell and molecular layer of the dentate gyrus. Cortical thickness increased in the temporal, parietal and insular cortices of the right hemisphere.
CONCLUSIONS
Following ECT structural changes were observed in hippocampal subfields and amygdala nuclei that are specifically implicated in the pathophysiology of depression and stress-related disorders and retain a high potential for neuroplasticity in adulthood.Declaration of interestS.K. has received grants/research support, consulting fees and/or honoraria within the past 3 years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe and Servier. R.L. received travel grants and/or conference speaker honoraria from Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, and Roche Austria GmbH.
Identifiants
pubmed: 30442205
pii: S0007125018002246
doi: 10.1192/bjp.2018.224
pmc: PMC6383756
mid: EMS79846
doi:
Banques de données
ClinicalTrials.gov
['NCT02379767']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-167Subventions
Organisme : Austrian Science Fund FWF
ID : P 27141
Pays : Austria
Commentaires et corrections
Type : CommentIn
Références
Am J Psychiatry. 2015 Jan;172(1):52-8
pubmed: 25157964
Biol Psychiatry. 2016 Feb 15;79(4):282-92
pubmed: 25842202
Eur J Neurosci. 1998 Jun;10(6):2163-72
pubmed: 9753102
Biol Psychiatry. 2004 Aug 1;56(3):151-60
pubmed: 15271583
Neurosci Lett. 2012 May 10;516(1):24-8
pubmed: 22465249
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):E563-72
pubmed: 22331913
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Mol Psychiatry. 2013 Jan;18(1):93-100
pubmed: 22751491
Sci Rep. 2018 Apr 3;8(1):5434
pubmed: 29615675
J Affect Disord. 2015 Nov 1;186:186-91
pubmed: 26247910
J Affect Disord. 2016 Nov 15;205:130-137
pubmed: 27434117
J Cereb Blood Flow Metab. 2014 Jul;34(7):1096-103
pubmed: 24802331
Mol Psychiatry. 2018 Mar;23(3):521-532
pubmed: 28809399
Eur Neuropsychopharmacol. 2016 Mar;26(3):506-17
pubmed: 26792445
Neuroimage. 2017 Apr 1;149:23-32
pubmed: 28119137
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Neuroimage. 2017 Jul 15;155:370-382
pubmed: 28479476
Neuropsychopharmacology. 2013 May;38(6):1068-77
pubmed: 23303074
Nature. 2011 Aug 03;476(7361):458-61
pubmed: 21814201
Eur Neuropsychopharmacol. 2009 May;19(5):329-38
pubmed: 19176277
Biol Psychiatry. 2013 Jul 1;74(1):62-8
pubmed: 23419546
Neuropsychopharmacology. 2018 Apr;43(5):1078-1087
pubmed: 28758644
Biol Psychiatry. 2018 Oct 15;84(8):574-581
pubmed: 30006199
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Eur J Neurosci. 2002 Jul;16(2):283-90
pubmed: 12169110
Nat Neurosci. 2015 Nov;18(11):1606-16
pubmed: 26389840
Neuroimage. 2015 Mar;108:243-50
pubmed: 25536499
Biol Psychiatry. 2015 Feb 1;77(3):285-294
pubmed: 25109665